Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1992 1
1997 2
1999 2
2000 1
2001 1
2002 2
2003 1
2004 9
2005 3
2006 9
2007 3
2008 8
2009 12
2010 17
2011 19
2012 12
2013 8
2014 25
2015 21
2016 24
2017 25
2018 38
2019 45
2020 44
2021 46
2022 54
2023 58
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

454 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 20ZY, 5BAuthor
Page 1
Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial.
Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, Ambler G, Bunce C, Wormald R, Nathwani N, Barton K, Rubin G, Buszewicz M; LiGHT Trial Study Group. Gazzard G, et al. Lancet. 2019 Apr 13;393(10180):1505-1516. doi: 10.1016/S0140-6736(18)32213-X. Epub 2019 Mar 9. Lancet. 2019. PMID: 30862377 Free PMC article. Clinical Trial.
The primary outcome was health-related quality of life (HRQoL) at 3 years (assessed by EQ-5D). Secondary outcomes were cost and cost-effectiveness, disease-specific HRQoL, clinical effectiveness, and safety. ...FINDINGS: Of 718 patients enrolled, 356 were randomised to the …
The primary outcome was health-related quality of life (HRQoL) at 3 years (assessed by EQ-5D). Secondary outcomes were cost and cost- …
Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre, randomised controlled trial: design and methodology.
Gazzard G, Konstantakopoulou E, Garway-Heath D, Barton K, Wormald R, Morris S, Hunter R, Rubin G, Buszewicz M, Ambler G, Bunce C; LiGHT Trial Study Group. Gazzard G, et al. Br J Ophthalmol. 2018 May;102(5):593-598. doi: 10.1136/bjophthalmol-2017-310877. Epub 2017 Sep 13. Br J Ophthalmol. 2018. PMID: 28903966 Clinical Trial.
The primary outcome measure is health-related quality of life (HRQL) (EQ-5D five-level). Secondary outcomes are treatment pathway cost and cost-effectiveness, Glaucoma Utility Index, Glaucoma Symptom Scale, Glaucoma Quality of Life, objective measures of pathway effectiven …
The primary outcome measure is health-related quality of life (HRQL) (EQ-5D five-level). Secondary outcomes are treatment pathway cos …
64Cu-1,4,7,10-Tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid agouti-related protein-7C.
Leung K. Leung K. 2010 May 23 [updated 2010 Jul 16]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2010 May 23 [updated 2010 Jul 16]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20662138 Free Books & Documents. Review.
Knottin 2.5D was labeled with N-succinimidyl-4-[(18)F]fluorobenzoate ([(18)F]SFB) to form 4-[(18)F]fluorobenzoyl-knottin 2.5D ([(18)F]FB-2.5D), which was evaluated for imaging tumor xenografts in mice with positron emission tomography (PET) (16). ...AgRP-7C p …
Knottin 2.5D was labeled with N-succinimidyl-4-[(18)F]fluorobenzoate ([(18)F]SFB) to form 4-[(18)F]fluorobenzoyl-knottin 2.5D …
Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States.
Zhang S, Bensimon AG, Xu R, Jiang R, Greatsinger A, Zhang A, Fukunaga-Kalabis M, Krepler C. Zhang S, et al. Adv Ther. 2023 Jul;40(7):3038-3055. doi: 10.1007/s12325-023-02525-x. Epub 2023 May 16. Adv Ther. 2023. PMID: 37191852 Free PMC article.
Costs were estimated in 2022 US dollars. Utilities were based on applying US value set to EQ-5D-5L data collected in trial and literature. RESULTS: Compared to observation, pembrolizumab increased total costs by $80,423 and provided gains of 1.17 quality-adjusted life year …
Costs were estimated in 2022 US dollars. Utilities were based on applying US value set to EQ-5D-5L data collected in trial and litera …
Estimating an EQ-5D-Y-3L Value Set for China.
Yang Z, Jiang J, Wang P, Jin X, Wu J, Fang Y, Feng D, Xi X, Li S, Jing M, Zheng B, Huang W, Luo N. Yang Z, et al. Pharmacoeconomics. 2022 Dec;40(Suppl 2):147-155. doi: 10.1007/s40273-022-01216-9. Epub 2022 Nov 18. Pharmacoeconomics. 2022. PMID: 36396878 Free PMC article.
This study aims to estimate an EQ-5D-Y-3L value set for China following this protocol, but with a larger cTTO design to better understand the role of cTTO data in estimating EQ-5D-Y-3L value sets. ...DISCUSSION: Following the international protocol and using a large …
This study aims to estimate an EQ-5D-Y-3L value set for China following this protocol, but with a larger cTTO design to better unders …
New phorbol ester derivatives as potent anti-HIV agents.
Li QR, Cheng YY, Zhao L, Huang XL, Jiang XG, Cui YD, Morris-Natschke SL, Goto M, Chen CH, Lee KH, Chen DF, Zhang J. Li QR, et al. Bioorg Med Chem Lett. 2021 Oct 15;50:128319. doi: 10.1016/j.bmcl.2021.128319. Epub 2021 Aug 14. Bioorg Med Chem Lett. 2021. PMID: 34403728
We synthesized and evaluated 29 new phorbol ester derivatives for anti-HIV activity and for cytotoxicity against human tumor cell lines. Among them, three derivatives, two phorbol-13-monoesters (5d and 5e) and a phorbol-12,13-diester (6a), showed significant anti-HIV activ …
We synthesized and evaluated 29 new phorbol ester derivatives for anti-HIV activity and for cytotoxicity against human tumor cell lines. Amo …
Exploring the Internal Structure of the EQ-5D Using Non-Preference-Based Methods.
Feng YS, Jiang R, Kohlmann T, Pickard AS. Feng YS, et al. Value Health. 2019 May;22(5):527-536. doi: 10.1016/j.jval.2019.02.006. Value Health. 2019. PMID: 31104730 Free article.
OBJECTIVES: To explore psychometrically derived approaches of elucidating the 5-level EQ-5D (EQ-5D-5L) item structure. METHODS: Three measurement models were assessed. ...The evidence calls for testing of formative/reflective combination approaches to summarize the …
OBJECTIVES: To explore psychometrically derived approaches of elucidating the 5-level EQ-5D (EQ-5D-5L) item structure. METHODS …
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
Khattak MA, Luke JJ, Long GV, Ascierto PA, Rutkowski P, Schadendorf D, Robert C, Grob JJ, de la Cruz Merino L, Del Vecchio M, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Carlino MS, Mohr P, De Galitiis F, Ross MI, Eroglu Z, Chen K, Jiang R, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Kirkwood JM. Khattak MA, et al. Eur J Cancer. 2022 Nov;176:207-217. doi: 10.1016/j.ejca.2022.08.004. Epub 2022 Oct 3. Eur J Cancer. 2022. PMID: 36202690 Free article. Clinical Trial.
Change in EORTC QLQ-C30 functioning, symptom, and single-item scales, and EQ-5D-5L visual analog scale (VAS) were also summarized. Primary analyses were performed at week 48 to ensure adequate completion/compliance. ...EORTC QLQ-C30 GHS/QoL, physical functioning, role func …
Change in EORTC QLQ-C30 functioning, symptom, and single-item scales, and EQ-5D-5L visual analog scale (VAS) were also summarized. Pr …
454 results